Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
DRTS
SELLAlpha Tau Medical Ltd. · Healthcare · Israel · $1.1B · Avg Vol: $9M/d
COMPANY DESCRIPTION
Alpha Tau Medical Ltd. is a clinical-stage oncology company developing Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), an innovative treatment for solid tumors using localized alpha-radiation. The company's proprietary technology directly targets tumors with high-energy alpha particles, aiming for potent and precise tumor destruction with minimal impact on surrounding healthy tissue. Alpha Tau Medical holds a unique position in oncology by advancing a differentiated alpha-radiation therapy for a broad range of cancers.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | 1.6M | 12.4M | — |
| EPS | -0.53 | -0.42 | -0.45 | -0.53 | — | -0.67 | -0.66 | -0.51 | — |
| Shares | 69.1M | 69.7M | 70.4M | 88.0M | +27.4% | 90.3M | — | — | — |
| Debt | 5.2M | 13.3M | 12.5M | 13.7M | 38.3% | 14.3M | — | — | — |
| Equity | 105.7M | 84.5M | 62.7M | 77.1M | -10.0% | — | — | — | — |
| Op CF | -23.9M | -18.0M | -19.8M | -26.7M | — | — | — | — | — |
| Inv CF | -89.9M | 18.7M | 20.8M | -20.6M | — | — | — | — | — |
| Fin CF | 96.9M | 5.3M | 25.0K | 45.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DRTS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| DRTS | Alpha Tau Medical Ltd.(you) | $1.1B | 27 | SELL |
| SLGL | Sol-Gel Technologies Ltd. | $268M | 34 | SELL |
| MDWD | MediWound Ltd. | $183M | 8 | STRONG SELL |
| ENTX | Entera Bio Ltd. | $101M | 16 | STRONG SELL |
| PYPD | PolyPid Ltd. | $75M | 22 | SELL |
| ENLV | Enlivex Ltd. | $71M | 12 | STRONG SELL |
| CGEN | Compugen Ltd. | $216M | 86 | STRONG BUY |
| BWAY | BrainsWay Ltd. | $641M | 51 | HOLD |
| INCR | InterCure Ltd. | $55M | 37 | HOLD |
| INMD | InMode Ltd. | $872M | 93 | STRONG BUY |
Peer medians: ROE 5.1% · P/E 16.0x · Gross margin 32.5%